Supriya Lifescience Q1 FY27 Earnings Call Transcript Released
Supriya Lifescience reported Q1 FY27 revenue of ₹190 crores, up 31% YoY. EBITDA was ₹47 crores, down 8.1%, with margins at 25% due to temporary water and power cost issues. The company reiterated its FY27 revenue target of ₹1,000 crores and EBITDA margin guidance of 33-35%. New product launches and the Patalganga facility development are progressing.
The revenue growth is positive, but the decline in EBITDA and margins due to external factors like water scarcity and increased power costs presents a short-term challenge. The company's confidence in future performance and reiteration of guidance mitigate a higher impact.
The company reported strong revenue growth, but a decline in EBITDA and margins due to temporary operational issues led to a neutral sentiment. While future outlook remains positive, the immediate financial performance was mixed.
Supriya Lifescience Limited has released the transcript of its earnings call for the quarter ended June 30, 2026, held on August 14, 2026. The company reported a revenue of ₹190 crores for Q1 FY27, a 31% year-on-year growth. However, EBITDA declined by 8.1% to ₹47 crores, with margins at 25%, impacted by temporary factors such as water scarcity due to delayed monsoons and increased fuel and power costs, which alone had an impact of ₹8 crores at EBITDA levels. Excluding these one-off impacts, margins would have remained within the guided range. The company expects performance to improve in coming quarters and remains on track to achieve its FY27 growth and margin objectives, targeting ₹1,000 crores in revenue by FY27 with EBITDA margins of 33% to 35%.
Exports contributed 81% of revenue, with Asia, Europe, and LATAM being key regions. The company is progressing with backward integration, reaching 72% of total revenues. New product launches are planned, including two anesthetic liquid inhalation products in Q2 FY27 and two ADHD products in the pipeline, with contrast media products expected in H2 FY27.
The company also provided updates on its Patalganga land development, with Phase 1 CAPEX earmarked at ₹200 crores for API and utility blocks. Regarding the Ambernath facility, an EU audit is scheduled for the second half of November. The company addressed concerns about a customs issue related to a specific consignment, stating that a new export authorization has been received and the matter is sub judice, with the consignment being of miniscule value and not impacting other exports. The company expects to recover the lost sales from Q1 in the coming quarters and is confident in achieving its full-year guidance.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.